Johnson & Johnson has announced that the U.S. Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application (sBLA) for Imaavy (nipocalimab-aahu), a potential treatment for warm autoimmune haemolytic anaemia (wAIHA). The designation accelerates the regulatory review process to approximately six months and is reserved for therapies that may offer significant improvements for serious conditions.

Warm autoimmune haemolytic anaemia is a rare and life-threatening disease in which the body’s immune system produces antibodies that destroy red blood cells, leading to anaemia and severe complications. Currently, there are no FDA-approved therapies specifically indicated for this condition, with patients largely dependent on broad immunosuppressive treatments such as corticosteroids.

Imaavy is designed to selectively block the neonatal Fc receptor (FcRn), thereby reducing levels of circulating immunoglobulin G (IgG), including harmful autoantibodies responsible for the disease, while preserving essential immune functions. This targeted approach distinguishes it from existing therapies that do not address the underlying cause of wAIHA.

The Priority Review decision is supported by data from the Phase II/III ENERGY clinical trial, which demonstrated that a higher proportion of patients treated with Imaavy achieved sustained improvements in haemoglobin levels compared to placebo. Patients also reported reduced fatigue, a key symptom affecting quality of life.

The drug is already approved for the treatment of generalized myasthenia gravis and is being evaluated across a range of autoimmune and antibody-mediated conditions. The latest designation underscores its potential as a first-in-class therapy for wAIHA and reflects the significant unmet medical need in this space.

Johnson & Johnson stated that it remains committed to advancing innovative immunology therapies and is actively exploring broader applications of nipocalimab across multiple rare and autoimmune diseases.